News

Public · Published

Phreesia's Sophia Wagner Named to Becker's 2026 List of Health IT & Revenue Cycle Up-and-Comers

Phreesia said Vice President of Product Engineering Sophia Wagner was named to Becker's Hospital Review's 2026 Health IT & Revenue Cycle Up-and-Comers list. Wagner leads product, engineering and operations teams for Phreesia's payments and provider financing businesses, overseeing nearly $5 billion in annual payment processing volume.

Published:

Updated:

What happened

Phreesia said Vice President of Product Engineering Sophia Wagner was named to Becker’s Hospital Review’s 2026 Health IT & Revenue Cycle Up-and-Comers list. Wagner leads product, engineering and operations teams for Phreesia’s payments and provider financing businesses, overseeing nearly $5 billion in annual payment processing volume.

Confirmed

Global impact / market context

The recognition highlights a leader overseeing products tied to patient payments, billing and provider financing. If her teams execute effectively, these offerings could support Phreesia’s ability to process payments and develop financing services; the announcement itself does not report a change in revenue or financial results.

Analyst inference

The article presents the listing as recognition of emerging healthcare technology and revenue-cycle leaders, based on nominations and editorial research. It gives no new financial guidance, customer figures or operating results, so the announcement alone offers limited evidence of a near-term change in Phreesia’s business performance.

Confirmed

What to watch

  1. Look for Phreesia disclosures on payment processing volume, which is the value of payments handled, to see whether the business overseen by Wagner is expanding. Analyst inference
  2. Watch for updates on provider financing after Phreesia’s acquisition of AccessOne, including evidence that the financing capabilities are being further developed. Confirmed
  3. Future company results could clarify whether product execution translates into revenue, costs or cash available; the article provides no figures showing such effects. Analyst inference

Evidence

  • Original source link unavailable